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Background: Olfactory function tests are sensitive tools for assessing sensory-cognitive processing in schizophrenia.
However, associations of central olfactory measures with clinical outcome parameters have not been simultaneously
studied in large samples of schizophrenia patients.
Methods: In the framework of the comprehensive phenotyping of the GRAS (Göttingen Research Association for
Schizophrenia) cohort, we modified and extended existing odor naming (active memory retrieval) and interpretation
(attribute assignment) tasks to evaluate them in 881 schizophrenia patients and 102 healthy controls matched for
age, gender and smoking behavior. Associations with emotional processing, neuropsychological test performance
and disease outcome were studied.
Results: Schizophrenia patients underperformed controls in both olfactory tasks. Odor naming deficits were
primarily associated with compromised cognition, interpretation deficits with positive symptom severity and
general alertness. Contrasting schizophrenia extreme performers of odor interpretation (best versus worst percentile;
N=88 each) and healthy individuals (N=102) underscores the obvious relationship between impaired odor
interpretation and psychopathology, cognitive dysfunctioning, and emotional processing (all p<0.004).
Conclusions: The strong association of performance in higher olfactory measures, odor naming and interpretation,
with lead symptoms of schizophrenia and determinants of disease severity highlights their clinical and scientific
significance. Based on the results obtained here in an exploratory fashion in a large patient sample, the
development of an easy-to-use clinical test with improved psychometric properties may be encouraged.
Keywords: Odor naming, Higher olfactory processing, Odor interpretation, Positive symptoms, CognitionBackground
The sense of smell and its relation to neurological and
psychiatric diseases is a field of growing interest in clinical
research. Like other neuropsychological measures, it
provides the opportunity to assess brain function in a
non-invasive way [1]. Central neural circuits underlying
olfactory function can be mapped to temporolimbic
and frontal brain regions [2]. Dysfunctional connectivity* Correspondence: ehrenreich@em.mpg.de
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reproduction in any medium, provided the orin these olfactory structures has been consistently im-
plicated in the affective and cognitive symptomatology
of schizophrenia patients [3]. Consequently, olfactory
tasks serve as behavioral probes to assess the structural
and functional integrity of neural substrates underlying
disturbed sensory-cognitive and emotional processing in
schizophrenia [3].
Olfactory input triggers cognitive events, often in
form of autobiographical memories [4-6]. Tests measuring
olfactory cognition address the disturbed integration of
olfactory input into cognitive processing. They share the
common principle of administering an odorant prior to
the execution of related mental operations with varying
degrees of difficulty [7]. The more demanding the olfactoryLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cortical olfactory circuits. Where in the olfactory projection
cascade difficulties for schizophrenia individuals arise is
still unclear [8]. Nevertheless, evidence of a peripheral
deficit in terms of abnormal olfactory receptor function
accumulated over the past years [9,10]. Profound problems
consistently emerge in schizophrenia patients when the
olfactory task requires basal cognitive operations like the
passive recognition of a presented odor from lists of
distractors (passive odor identification) [11-13], or when
a delay between odor presentation and identification is
introduced (odor memory) [4,14].
The identification and explicit naming of odorants
(active odor naming) is a complex task requiring correct
smell encoding, semantic memory, and selection of the
most appropriate denomination [15]. Saoud and coworkers
delivered first evidence of an odor naming deficit in a small
sample (N=24) of male schizophrenia patients [16]. An
implication of dorsolateral prefrontal executive functioning
networks in this task was supported by its correlation
with Wisconsin Card Sorting Test performance [16].
Surprisingly, clinical variables like PANSS scores or age at
onset did not correlate with odor naming ability in this
study [16]. Although less cognitively demanding, asso-
ciations with schizophrenia psychopathology including
cognition have been consistently shown for passive odor
identification [8,17-19]. The missing link between PANSS
scores and odor naming ability in the study by Saoud and
coworkers likely reflects a lack of statistical power due to
the very small sample size (N=24). As it is a very elegant
and naturalistic measure of the integrity of prefrontal
networks, we decided to extend in the present study the
work reported by Saoud and colleagues by evaluating
odor naming performance and its relationship with clinical
and cognitive variables in a large sample of schizophrenia
patients.
Olfactory stimuli do not only induce cognitive activity,
they immediately evoke emotional reactions [20]. To
explore the nature of affective states in response to different
scents, available olfactory function tests require the judge-
ment of various qualities of given odors. Schizophrenia
subjects are less accurate when deciding whether an odor
is edible, pleasant or familiar as compared to healthy
controls [21-24]. It is known that the rating of gusta-
tory or semantic properties of odors facilitates their
subsequent naming in healthy control subjects [25].
No study has ever investigated whether schizophrenia
patients have difficulties in judging gustatory (sweet, hot)
or semantic properties (association of an odor with its
context, i.e. technical or natural) of odors beyond familiar-
ity, hedonicity and edibility ratings (odor interpretation).
Moreover, it has not been evaluated how the inability to
accurately interpret olfactory stimuli relates to schizophrenia
symptomatology.As a part of the very comprehensive phenotyping of the
GRAS cohort [26], odor interpretation and naming was
evaluated in 881 schizophrenia patients and 102 healthy
matched controls. In the present study we assessed odor
naming and interpretation ability using diverse odors
typical for the ‘olfactory environment’ of German subjects
as well as descriptive attributes (hedonic, gustatory and
semantic). We evaluated the relationship of olfactory task
performance with relevant symptom domains and clinical
outcome measures in the whole schizophrenia sample
(N=881) and, subsequently, in extreme groups of odor
interpretation performance (best versus worst percentile),




The present study (GRAS project) was approved by ethics
committees of the Georg-August-University Göttingen
(master committee) and collaborating centers. Detailed
phenotyping of the GRAS sample [26] contained odor
naming and odor interpretation tasks (Figure 1A), ad-
ministered to 999 schizophrenia patients after written
informed consent. Present analyses excluded all non-native
German speakers (N=89), all patients with known anosmia
(N=14, neurological conditions e.g. head injury, or cold)
and 6 patients with missing data. Nine patients were
excluded as non-admissible based on performance in entry
and odor naming tasks (Figure 1B). Data analyses were
based on the remaining 881 patients.
Healthy controls
As comparison group, 103 healthy subjects matched for
age, gender and smoking status (smoker: yes/no) were
recruited by public announcements and gave written
informed consent. They were free of any physical, neuro-
logical and psychiatric disorder, and had no relatives with
a history of neuropsychiatric diseases. One individual
was excluded due to his performance in entry and odor
naming tasks. Data analyses were based on 102 controls.
Measures
Olfaction
Odorants The University of Pennsylvania Smell Identifica-
tion Test [27] (UPSIT) is the olfactory function test most
widely applied clinically and scientifically. It has been used
as validation criterion for newly developed olfactory tests
[28]. A total of 10 different scents (scratch and sniff format)
were selected from this battery (for detailed description of
the administration procedure see [11]). Odorants were
chosen by an experienced psychiatrist based on following
criteria: (I) For the entry odor task, odors had to be easily
identifiable (low item difficulty) to minimize contribution






























































Theoretical binomial probabilities for random guessing
a1 or 2 missing values (out of 4) were imputed for N=21 schizophrenia subjects. All other subjects had complete data in the
entry task. bStill including the N=9 schizophrenia / N=1 healthy subjects that were identified by the entry task and odor
naming as non-admissible and excluded from remaining analyses.












































aReasoning: Higher values mean better performance. bPsychopathology and emotional processing deficits: Higher values mean
more severe symptomatology. Abbreviations: LPS 3=Leistungsprüfsystem (subtest 3); Con=Healthy controls; HIP= High odor





































Figure 1 Design of odor tasks and overview of main results. (A) After completion of the entry odor task (passive recognition of 4 odors -
multiple choice), subjects were asked to assign a set of attributes (odor interpretation) and then to name the respective odorant (odor naming),
consecutively for 6 odors. (B) The entry odor task revealed a clear contrast between test results (schizophrenia patients, healthy controls) and
theoretical binomial probabilities for guessing subjects. (C) The main findings of the study are summarized. Low interpretation performers (LIP)
showed worse reasoning abilities, a more severe psychopathology and emotional processing deficits.
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ficulties to differentiate between subjects along the whole
spectrum of cognitive abilities. For odor interpretation,
items of low difficulty were chosen due to the expected
profound interpretation deficit in schizophrenia. (II) The
odors had to be of high ecological validity to German
subjects. (III) To balance avoidance of redundancy (due
to time limitations) and reliability, odors were selected to
represent diverse associated contexts (e.g. rose and petrol)
and attribute overlap (both pineapple and licorice are
pleasant and sweet). Although this study was not designed
to introduce a new ready-to-be-used olfaction test, prelim-
inary item characteristics and psychometric properties are
provided in Table 1.
Entry odor task To be able to interpret odor naming
and interpretation results as central processing deficits,
an entry odor task (Figure 1A; maximum score 4) was
introduced. A total of 4 consecutively presented odors
are chosen from 4 alternative descriptors each (multiplechoice, brief passive odor identification [11]) by pointing
to or naming the correct term on the scoring sheet. The
entry task should identify potentially anosmic subjects
unaware of their condition or failing to report it prior to
performing odor naming and interpretation tasks. The 4
odorants lemon, smoke, lilac and paint thinner were chosen
to be easily identifiable (Table 1) and representative of all
attributes contained in the odor interpretation task. Lemon
was selected to cover the attributes sweet and edible, lilac is
an odor judged as pleasant and natural, smoke is hot and
dangerous and paint thinner is often associated with a
technical context. Figure 1B shows that theoretical
binomial probabilities for random guessing (in case of
anosmia or pronounced cognitive impairment, assuming
equal multiple-choice success probabilities of 0.25 for all 4
odors) markedly differed from relative recognition score
frequencies. The vast majority of patients and controls
recognized 3–4 odors correctly whereas 95% of guessing
subjects would recognize <3 odors correctly in the entry
task. Simultaneously, guessing would result in an odor
Table 1 Psychometric properties of odor interpretation and odor naming tasks in the schizophrenia sample (N=881)
Odor naminga Odor interpretation (odors)b Odor interpretation (attributes)b
Item difficulty (weighted % correct naming ± 95%CI)
Pineapple 21.71 ± 0.01 73.0 ± 1.7 Pleasant 81.7 ± 1.2
Petrol 38.67 ± 0.02 78.2 ± 1.3 Sweet 72.6 ± 1.1
Mint 76.35 ± 0.03 78.0 ± 1.2 Hot 69.5 ± 1.4
Rose 39.99 ± 0.02 80.2 ± 1.3 Technical 81.3 ± 1.1
Natural gas 16.61 ± 0.02 70.9 ± 1.6 Natural 75.1 ± 1.3
Licorice 54.48 ± 0.03 82.3 ± 1.3 Edible 80.4 ± 1.2
Dangerous 79.5 ± 1.1
Item discrimination, part-whole corrected [95%CI]
Pineapple 0.24 [0.18, 0.30] 0.21 [0.15,0.27] Pleasant 0.46 [0.40,0.51]
Petrol 0.25 [0.19, 0.31] 0.25 [0.19,0.31] Sweet 0.33 [0.27,0.39]
Mint 0.30 [0.24, 0.36] 0.27 [0.20,0.33] Hot 0.18 [0.11, 0.24]
Rose 0.28 [0.21, 0.34] 0.18 [0.11,0.24] Technical 0.58 [0.53, 0.62]
Natural gas 0.13 [0.07, 0.20] 0.16 [0.09,0.22] Natural 0.45 [0.40,0.50]
Licorice 0.27 [0.20, 0.33] 0.20 [0.14,0.27] Edible 0.52 [0.47,0.56]
Dangerous 0.52 [0.47,0.56]
Item discrimination, not part-whole corrected [95%CI]
Pineapple 0.41 [0.35, 0.46] 0.57 [0.52,0.61] Pleasant 0.63 [0.59,0.67]
Petrol 0.50 [0.45, 0.54] 0.53 [0.48,0.58] Sweet 0.52 [0.47,0.56]
Mint 0.60 [0.55, 0.64] 0.52 [0.47,0.57] Hot 0.44 [0.38,0.49]
Rose 0.56 [0.51, 0.61] 0.45 [0.40,0.50] Technical 0.72 [0.69,0.75]
Natural gas 0.33 [0.26, 0.39] 0.50 [0.45, 0.55] Natural 0.64 [0.60,0.68]
Licorice 0.65 [0.62, 0.69] 0.48 [0.43,0.53] Edible 0.68 [0.64,0.71]
Dangerous 0.66 [0.62,0.70]
Internal consistency (standardized Cronbach’s α, equals average split-half reliability)
0.50 [0.47, 0.54] 0.44 [0.40,0.48] 0.72 [0.71,0.74]
Abbreviations: CI, confidence interval. aPsychometric measures were calculated based on Spearman correlation (ordinal data). bPsychometric measures were
calculated based on Pearson correlation (metric data).
Kästner et al. BMC Psychiatry 2013, 13:218 Page 4 of 12
http://www.biomedcentral.com/1471-244X/13/218naming score of 0 (free choice test) which is extremely
unlikely (Figure 2B). Consequently, subjects were excluded
from analysis when they had less than 3 out of 4 correctly
recognized odors in the entry task and an odor naming
score of 0 (9 schizophrenia subjects, 1 healthy control
subject) because of potentially experiencing difficulties at
the peripheral processing level. Clearly, this approach risks
excluding cognitively extremely impaired individuals.
Indeed, excluded individuals cognitively underperformed
the 881 schizophrenia subjects (881 subjects: -0.03 ± 0.78;
9 excluded subjects: -0.92 ± 0.54; mean ± SD of higher
cognition composite; see below).
Odor naming and odor interpretation The odor nam-
ing task (maximum score 18) measures the correct naming
of the 6 odors pineapple, petrol, mint, rose, natural gas and
licorice (free choice; Figure 1A). Three points were scored
for the correct name, 1 point if the subject provided an
item belonging to the same semantic category (e.g.pineapple: 3 points for ‘pineapple’, 1 point for ‘fruit’).
Before naming an odor, probands had to decide whether it
matched the 7 attributes pleasant (hedonic judgement),
sweet & hot (gustatory judgement), technical, natural,
edible and dangerous (semantic judgement) (forced choice:
‘yes’ or ‘no’ answer; odor interpretation; same set of odors
as for naming) (Figure 1A). One point was scored for each
attribute assignment consistent with the predefined profile
(maximum score 42=6x7). Although task reliability im-
proves with number of items [29], we had to restrict it to
6 items for time-economic reasons (olfactory tasks being
only a fraction of the GRAS examination procedure [26]).Disease-relevant possible confounders
As unspecific but disease-relevant (overall severity) possible
confounders, duration of disease, number of hospitalizations
and medication status (chlorpromazine equivalents) were
selected.
Odor interpretation sum score
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High Interpretation Performers (N=88)
Low Interpretation Performers (N=88)
C
0.46 points, 95%CI [-0.27,  1.20], p=0.22a,c 
-4.67 points, 95%CI [-5.41, -3.94], p=9.1x10-29a,d
-5.15 points, 95%CI [-5.92, -4.38], p=7.0x10-28a,e
aLinear regression on the standardized (Blom-transformed) trait, adjusting for linear age-dependence and for gender (naming). Smoking status did not significantly
influence naming, nor interpretation. bSchizophrenia compared to healthy subjects (test statistic t979=-6.318 (interpretation), t978=-5.993 (naming)). cSchizophrenia HIP
compared to healthy subjects (t273=1.234). dSchizophrenia LIP compared to healthy subjects (t273=-12.533). eSchizophrenia LIP compared to schizophrenia HIP (t172=-
13.183). Abbreviations : CI= Confidence interval; HIP= High odor interpretation performers; LIP= Low odor interpretation performers.
Figure 2 Odor naming and interpretation sum scores in patients and healthy controls and extreme group comparison based on odor
interpretation performance. (A) Schizophrenia subjects experience severe problems in the correct interpretation of odors compared to
matched healthy controls (p<0.000001). (B) Schizophrenia subjects are significantly impaired in the odor naming task compared to matched
healthy controls (p<0.000001). (C) Extremely poor schizophrenia interpretation performers (LIP) display worse odor naming results compared to
schizophrenia high interpretation performers (HIP) and to healthy control subjects.
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cognition and emotional processing
To address schizophrenia relevant target domains, age-at-
prodrome, general assessment of functioning (GAF) scale,
PANSS (positive and negative syndrome scale) subscales
[30], a higher cognition composite (comprising neuro-
psychological measures listed in Table 2), and the alertness
subtest (mean of tonic and phasic alertness) of TAP
(Testbatterie für Aufmerksamkeitsprüfung [31], English
translation: Test battery for attention) were included.
MacQuarrie dotting and tapping tests [32] were integratedTable 2 Presentation of high (HIP) and low (LIP) interpretatio
composite components and emotional processing items
Desc
SZ LIP
Higher cognition composite components
Reasoningc mean ± SD 20.8 ± 6.6 18.2 ±
range (2–38) (2–34
Executive functioningc median −56.5 −79.0
interquartile [−103.0, -36.0] [−139
range (−868– 40) (−680
Working memoryc mean ± SD 13.1 ± 3.9 11.7 ±
range (1–24) (4–22
Processing speedc mean ± SD 38.4 ± 13.2 32.5 ±
range (4–88) (5–68
Verbal memoryc mean ± SD 42.0 ± 12.6 37.3 ±
range (6–72) (11–6
Divided attentionc median −725 −764
interquartile [−806, -659] [−833
range (−1663– -355) (−116
Emotional processing items
Blunted affect median 3 4
(PANSS N1) interquartile [2,4] [3,5]
range (1–7) (1–7)
Emotional withdrawal median 3 3
(PANSS N2) interquartile [1,4] [1,4]
range (1–7) (1–7)
Poor rapport median 2 3
(PANSS N3) interquartile [1,3] [1,4]
range (1–7) (1–6)
Multiple testing adjusted significances are set in boldface (p≤0.0083 for component
other p-values≤0.05 in italic. at-Statistic tdf with df degrees of freedom for estimatio
bWilcoxon rank sum test. cAdjusted for age and PANSS negative. Reasoning ability w
execution times between TMTA and TMTB, working memory was assessed by BZT,
negative execution time (−d3mdg) of TAP. In this table, and when building the cog
represent better cognitive performance. Abbreviations: SZ= Descriptive statistics for
LIP= Low interpretation performers (N=88); LPS3= Subtest 3 of the Leistungsprüfsys
Trail Making Test A and B; BZT=Letter Number Sequencing; ZST= Digit Symbol Cod
Aufmerksamkeitsprüfung, English translation: Test battery for attention. All neuropsinto a fine motor function composite. The Mehrfachwahl-
Wortschatz-Test [33] (MWTB, English translation: Mul-
tiple Choice Vocabulary Test of Intelligence) covered
premorbid intelligence. Emotional processing was opera-
tionalized as sum score of ‘blunted affect’, ‘emotional with-
drawal’ and ‘poor rapport’ of PANSS, as previous studies
have shown that amygdala responses to facial emotional
expression correlate with the negative subscale of PANSS
[34]. Higher scores represent worse outcome in PANSS
but better performance in GAF and neuropsychological
tests. Healthy controls completed odor naming andn performer profiles with respect to higher cognition
riptive LIP compared to HIP
HIP Effect p
[95%CI] (Statistic)
6.7 21.5 ± 6.5 −2.61 3.6x10-3
) (8–38) [−4.35, -0.86] (t164=−2.951
a)
−47.0 −24.77 0.082
.0, -47.0] [−122.0, -34.0] [−52.69, 3.15] (t155=−1.753
a)
– -9) (−563– -10)
4.4 13.6 ± 3.9 −1.25 0.049
) (4–24) [−2.50, -0.00] (t158=−1.981
a)
13.7 39.3 ± 13.5 −4.52 0.011
) (6–71) [−7.99, -1.04] (t167=−2.566
a)
12.5 43.0 ± 14.0 −3.38 0.083
2) (6–70) [−7.22, 0.45] (t161=−1.742
a)
−714 4.14 0.84
, -651] [−797, -647] [−35.50, 43.78] (t158= 0.206
a)










s of higher cognition composite, p≤0.0167 for emotional processing items). All
n of difference in means (employing a linear model on Blom-transformed trait).
as measured by LPS3, executive functioning is represented as difference of
processing speed by ZST, verbal memory by VLMT and divided attention by
nition composite, all measures were presented such that larger values
schizophrenia sample (N=881); HIP= High interpretation performers (N=88);
tem, a German test covering Thurstone’s primary mental abilities; TMTA/B=
ing; VLMT= Verbal Learning and Memory Test; TAP=Testbatterie für
ychological measures are cited in Ribbe et al. 2010.
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[35]; MWTB [33]; subtests dotting and tapping subtests of
the MacQuarrie test for mechanical ability [32]). All tests
are cited in [26].
Statistical analyses
To test for associations of odor naming and interpretation
performance with disease-relevant symptom domains,
multiple linear regression was applied within the schizo-
phrenia sample (Table 3). The model simultaneously tested
for linear dependence of the target (odor naming or odor
interpretation performance) on a set of multiple predictor
variables (cognitive performance, symptom severity and
control variables) while adjusting for gender (odor naming)
and for linear age-dependence (odor naming and odor
interpretation). Displayed regression coefficients are
mutually adjusted for the respective other predictors. All
variables were a priori standardized such that regression
coefficients quantify relative association strengths interpret-
able in analogy to Cohen’s d, displaying mutually adjusted
relative association strengths interpretable in analogy to
Cohen’s d). Sum scores for higher cognition and fine
motor performance are the mean of standardized neuro-
psychological measures in these domains (larger values
represent better performance). Rank-based Blom trans-
formation [36] was applied to standardize all measures by
transforming them into standard normally distributed sur-
rogates prior to sum score computation. This maintained
the order of the data, but removed skewness from variable
distributions. Group comparisons between healthy andTable 3 Odor naming is associated with cognition and odor i
alertness in schizophrenia subjects (N=881)
Odor nam








Fine motor function compositec,d −0.010
(t813=−0.2
Premorbid intelligence (MWTB)d 0.071
(t813= 1.7
aRelative association strength of domains with odor naming and odor interpretation
model containing linear terms for all six predictor variables (table rows) and adjusti
significances (Bonferroni p≤0.025) in boldface. bThe higher cognition composite inc
Leistungsprüfsystem, a German test covering Thurstone’s primary mental abilities), e
A and B), working memory (Letter Number Sequencing), processing speed (Digit Sy
attention (test battery for attention). cThe fine motor function composite consists o
dControl variables.schizophrenia subjects (Figure 2A-B), and schizophrenia
subgroups (Figure 1C, Figure 2C and Tables 2, 4 and 5)
were tested by linear regression (for standardized normally
distributed quantitative targets, adjusting for covariates
where indicated), Fisher’s exact test (for binary targets
gender, smoking and genetic risk status), or non-parametric
Wilcoxon rank sum test (for quantitative targets which
could not be standardized to normal distribution). For
linear model analyses, the target variable is denoted in
the table row, respectively. The tested predictor was
class membership, adjusting for linear dependence on
age, PANSS negative and for gender where indicated.
Standardized regression coefficients (with 95% confidence
limits) were converted to the original variable scale for
ease of interpretation by multiplication with the raw
data standard deviation of the target variable within the
respective data. Multiple-testing was accounted for by
Bonferroni correction and closed testing principle (Table 4).
All p-values are two-sided.
Results
Influence of age, smoking and gender on odor naming
and interpretation
Increasing age is associated with a decline in odor nam-
ing (average −0.05 points/year, p=2.2x10-11, test statistic
t978=−6.770) and interpretation performance (average −0.06
points/year, p=1.6×10-8, t979=−5.697) likewise in schizo-
phrenia and healthy individuals (no significant difference).
Smoking status had no influence on both central olfactory
measures. Women proved to be slightly superior to mennterpretation with severity of positive symptoms and
inga Odor interpretationa
0.057
47, p=0.019) (t814= 0.789, p=0.430)
0.196
01, p=0.001) (t814= 4.635, p=0.000)
−0.045
717, p=0.007) (t814=−1.073, p=0.283)
−0.107
07, p=0.160) (t814=−2.701, p=0.007)
0.017
10, p=0.834) (t814= 0.336, p=0.737)
0.059
61, p=0.079) (t814= 1.420, p=0.156)
(t-statistic tdf with df degrees of freedom, p value). Multiple linear regression
ng for age (odor naming and odor interpretation) and gender (odor naming),
ludes the following cognitive domains: Reasoning ability (subtest 3 of the
xecutive functioning (difference of execution times between Trail Making Test
mbol Coding), verbal memory (Verbal Learning and Memory Test) and divided
f dotting and tapping subtests of the MacQuarrie test for mechanical ability.
Table 4 Severely impaired interpretation performers (LIP) show compromised cognition compared to healthy controls
(Con) and non impaired interpretation performers (HIP)
Trait Descriptive Group contrast Effect [95%CI] Statistic p
Basic characteristics
Age (years) SZ 39.5 ± 13 (17–78)
mean ± SD (range) Con 38.8 ± 14 (18–71) HIP / Con 2.75 [−0.81, 6.31] t275= 1.522
a 0.13
HIP 41.0 ± 11 (22–64) LIP / Con 1.25 [−2.31, 4.81] t275= 0.693
a 0.49
LIP 39.7 ± 13 (18–71) LIP / HIP −1.40 [−4.58, 1.77] t174=−0.873
a 0.38
Gender (% female) SZ 33
Con 32 HIP / Con OR 1.25 [0.66, 2.38] Fisherb 0.54
HIP 38 LIP / Con OR 0.83 [0.42, 1.62] Fisherb 0.64
LIP 28 LIP / HIP OR 0.66 [0.33, 1.31] Fisherb 0.26
for females
Smoker status (% yes) SZ 48
Con 63 HIP / Con OR 0.45 [0.21, 0.94] Fisherb 0.025
HIP 43 LIP / Con OR 0.57 [0.26, 1.23] Fisherb 0.15
LIP 49 LIP / HIP OR 1.26 [0.52, 3.05] Fisherb 0.68
for smokers
Disease related higher and basal cognition and premorbid intelligence
Reasoningc SZ 20.8 ± 6.6 (2–38)
mean ± SD (range) Con 27.2 ± 5.2 (14–38) HIP / Con −3.00 [−4.86, -1.14] t265=−3.180
a 1.6x10-3
HIP 21.5 ± 6.5 (8–38) LIP / Con −5.49 [−7.63, -3.35] t265=−5.058
a 7.9 x10-7
LIP 18.2 ± 6.7 (2–34) LIP / HIP −2.45 [−4.07, -0.82] t164=−2.971
a 3.4 x10-3
Fine motor function SZ −0.12 ± 0.91 (−3.22–3.22)
compositec Con 0.97 ± 0.68 (−1.09–2.83) HIP / Con −0.53 [−0.75, -0.31] t268=−4.674
a 4.7 x10-6
mean ± SD (range) HIP −0.002 ± 0.87 (−2.40–1.83) LIP / Con −0.78 [−1.03, -0.52] t268=−5.951
a 8.3 x10-9
LIP −0.45 ± 0.93 (−2.89–1.90) LIP / HIP −0.23 [−0.41, -0.05] t167=−2.471
a 0.014
Premorbid SZ 26.2 ± 6.1 (4–37)
intelligenced Con 30.9 ± 4.0 (18–37) HIP / Con −0.22 [−2.06, 1.62] t267=−0.236
a 0.81
mean ± SD (range) HIP 27.8 ± 5.0 (13–37) LIP / Con −2.60 [−4.74, -0.46] t267=−2.393
a 0.017
LIP 23.8 ± 7.0 (5–35) LIP / HIP −2.51 [−4.19, -0.83] t166=−2.955
a 3.6 x10-3
Multiple testing adjusted significances (applying Bonferroni (p≤ 0.007) and the closed testing principle) are set in boldface. All other p-values 0.05 are set in italic;
at-Statistic tdf with df degrees of freedom for estimation of difference in means (employing a linear model on Blom-transformed trait);
bFisher’s exact test for count
data; cAdjusted for age at exam and PANSS negative (value 7 for healthy control). Reasoning ability was measured by LPS3 (subtest 3 of the Leistungsprüfsystem, a
German test covering Thurstone’s primary mental abilities). Fine motor function composite is the mean from standardized (by Blom-transformation) MacQuarrie
dotting and tapping; dAdjusted for age (age of onset of psychosis for schizophrenia HIP and LIP, age at exam for healthy control) and PANSS negative (value 7 for
healthy control). Premorbid intelligence was assessed by MWTB (Mehrfachwahl-Wortschatz-Intelligenztest, English translation: multiple choice vocabulary test of
intelligence). Abbreviations: Con= Healthy control (N=102); SZ= Descriptive statistics for whole schizophrenia sample (N=881); HIP= High interpretation performers
(N=88); LIP= Low interpretation performers (N=88), OR=Odds Ratio.
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but not interpretation.Odor naming and interpretation are impaired in
schizophrenia patients
The main study results are summarized in Figure 1C.
Inferior performance of schizophrenia patients (N=881)
compared to 102 matched healthy controls became evident
for odor interpretation and naming tasks (Figure 2A,B;
interpretation: p=4.0×10-10; naming: p=2.9×10-9).Odor naming and interpretation are differentially
associated with psychopathology and cognition
in schizophrenia patients
Odor naming and interpretation correlate substantially
(Spearman correlation r=0.51, 95%CI [0.46, 0.56],
p<2.2×10-16). To investigate relative association strengths
of odor naming and interpretation with 3 schizophrenia
relevant symptom domains (cognition, negative and posi-
tive symptoms) and 2 control variables (fine motor function
and premorbid intelligence) (Table 3), multiple linear
regression was applied in the schizophrenia sample
Table 5 Severely impaired interpretation performers (LIP) show a more severe psychopathology, compromised
cognition and emotional processing compared to high interpretation performers (HIP)
Descriptive LIP compared to HIP
SZ (N=881) LIP (N=88) HIP (N=88) Effect [95%CI] P (Statistic)
Disease relevant confounders
Years of education median 12.0 11.0 13.0 −1.55 5.4 x10-4
(years) interquartile [10.0, 13.5] [9.0,13.0] [10.0,15.0] [−2.42, -0.68] (t174=−3.525
a)
range (8.0-27.0) (8.0-20.5) (8.0-24.0)
Duration of disease median 11.0 13.7 11.1 0.28
(years) interquartile [4.7, 20.1] [6.4, 21.9] [5.3, 20.9] - (W=3466b)
range (0.008,58.4) (0.1, 47.4) (0.6, 45.3)
Number of median 3.0 3.0 4.0 0.10
hospitalizations interquartile [2.0, 6.0] [2.0, 5.0] [3.0, 6.0] - (W=2532b)
range (0, 55) (1, 44) (1, 50)
Chlorpromazine median 500 600 450 0.068
equivalents interquartile [250, 900] [300, 1072] [228, 817] - (W=3216b)
range (0, 7375) (0, 3238) (0, 3064)
Functional outcome, disease severity and psychopathology
General assessment of mean ± SD 45.6 ± 17.2 38.0 ± 17.1 49.8 ± 17.0 −11.93 6.5x10-6
functioning (GAF) range (5, 90) (10, 85) (20, 90) [−16.99, -6.87] (t171=−4.654
a)
Age-at-prodrome (years) median 20 19 23 −2.70 0.054
interquartile [17,26] [16,24] [17,30] [−5.44, 0.05] (t153=−1.942
a)
range (2, 66) (12, 66) (2, 47)
PANSS negative median 17.0 22.0 15.0 4.54 1.7 x10-4
interquartile [12.0, 23.0] [14.0, 27.0] [11.0, 21.8] [2.21, 6.88] (t171= 3.840
a)
range (7.0, 44.0) (7.0, 40.0) (7.0, 38.0)
PANSS positive median 12.0 15.0 11.0 3.96 1.6 x10-4
interquartile [9.0, 17.0] [10.0, 22.0] [8.0, 15.8] [1.94, 5.98] (t171= 3.869
a)
range (7.0, 38.0) (7.0, 37.0) (7.0, 38.0)
Disease-related cognition
Higher cognition mean ± SD −0.03 ± 0.78 −0.41 ± 0.84 0.07 ± 0.83 −0.24 4.3 x10-3
compositec range (−2.64, 1.93) (−2.64, 1.40) (−1.92, 1.77) [−0.40, -0.07] (t169=−2.896
a)
Alertness (TAP)c median −282 −331 −270 −80.75 1.4 x10-4
(msec) interquartile [−350, -245] [−479, -270] [−311, -237] [−121.61, -39.89] (t164=−3.902
a)
range (−1288, -163) (−1219, -206) (−878, -192)
Emotional processing items
PANSS negative median 8.0 10.0 7.0 3.3 x10-3
N1+N2+N3d interquartile [5.0, 11.0] [6.0, 12.3] [4.0, 11.0] - (W=2883b)
range (0.0, 21.0) (3.0, 18.0) (0.0, 16.0)
Multiple testing adjusted significances (Bonferroni: p≤0.0045) are set in boldfaces, all other p-values≤0.05 in italic. at-Statistic tdf with df degrees of freedom for estimation
of difference in means (employing a linear model on Blom-transformed trait; small differences in degrees of freedom are due to low percentages of missing trait values).
bWilcoxon rank sum test. cAdjusted for age and PANSS negative. dN1: Blunted affect, N2: Emotional withdrawal, N3: Poor rapport. Abbreviations: SZ= Descriptive statistics
for whole schizophrenia sample (N=881); HIP= High interpretation performers (N=88); LIP= Low interpretation performers (N=88), OR=Odds Ratio.
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ation strength (relative to the standard deviation of the
target trait). Odor naming and interpretation scores were
strongly dependent on alertness. Worse naming results
were additionally linked to impaired higher cognition andmore severe negative symptoms (PANSS). Deficits in odor
interpretation were associated with higher positive symp-
tom severity (PANSS). No significant link was detected
between odor naming or interpretation and fine motor
function or premorbid intelligence.
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performance reveal strong differences in several lead
symptom domains
The frequency distributions of interpretation and naming
scores (Figure 2A,B) showed increased probabilities of
low scores for schizophrenia patients, especially for odor
interpretation. This suggests that olfactory processing
deficits may be particularly pronounced in a subgroup of
schizophrenia patients. To achieve a maximum phenotypic
contrast, schizophrenia high interpretation performers
(HIP, scoring >90th percentile) were contrasted with low
interpretation performers (LIP, scoring <10th percentile;
N=88 each) and compared to healthy controls (Con,
N=102) with respect to basic sample characteristics, dis-
ease related higher and basal cognition and premorbid
intelligence. The 3 groups did not differ (pairwise com-
parisons) with regard to age, gender and smoking status.
Expectedly, a highly significant naming deficit became
obvious for LIP in comparison to HIP (p=7.0×10-28) and
healthy controls (p=9.1×10-29) (Figure 2C). In terms of
reasoning capabilities, healthy controls obtained better
results than schizophrenia HIP (p=1.6×10-3) with the
latter performing superior to LIP (Table 4, p=3.4×10-3)
(Figure 1C). For fine motor function, both schizophrenia
groups performed comparably and markedly worse than
healthy controls (HIP/LIP: p=0.015; HIP/Con: p=4.4×10-6;
LIP/Con: p=8.1×10-9). Also for premorbid intelligence,
a difference was observed between disease groups (HIP/
Con: p=0.81; LIP/Con: p=0.017; LIP/HIP: p=3.6×10-3)
(Table 4).
More detailed assessment of group contrast between
schizophrenia LIP compared to HIP in disease-related
domains, revealed higher severity of negative symptoms
(p=1.7×10-4) and positive symptoms (p=1.6×10-4) for LIP
(Figure 1C). Additionally, strongly impaired cognitive and
emotional processing became evident (higher cognition
composite: p=3.7×10-3; alertness: p=1.4×10-4; emotional
processing: p=3.3×10-3), resulting in a worse functional
outcome (p=6.5×10-6; average difference 12 GAF units) for
LIP (Table 5). Extreme group comparison for individual
neuropsychological measures (Table 2) revealed strongest
differences for reasoning (p=3.6×10-3) followed by pro-
cessing speed (p=0.011) and working memory (p=0.049).
Results for executive functioning, verbal memory and
divided attention failed to be significant. No significant
differences were observed with regard to possible con-
founders indicating overall disease severity (duration
of disease, number of hospitalizations and chlorpromazine
equivalents). Also, age-at-prodrome (median, range for
LIP: 19, 12–66, for HIP: 23, 2–47, p=0.054) and age-of-on-
set (LIP: 23, 15–67, HIP: 27, 8–55, p=0.0079) were only
close to or nominally significant, i.e. above the Bonferroni
corrected significance threshold (p>0.005). Together, the
results of the extreme group approach indicate thatdeficits in odor interpretation are accompanied by more
severe psychopathology, worse cognitive and emotional
processing and inferior functional outcome.
Discussion
The present study, building on and extending previous
work, demonstrates in a large sample of subjects that
the ability to name and qualitatively interpret odors is
markedly impaired in schizophrenia. Importantly, the
study adds new aspects to the available literature by
showing distinct associations between central olfactory
measures and schizophrenia-relevant clinical variables.
Extreme group comparisons providing maximum pheno-
typic contrast deliver further evidence for a biological
subgroup of patients, defined by a severe olfactory dys-
function. This subgroup is characterized by profound
abnormalities in higher olfactory processing, together
with a more severe psychopathology, remarkable cognitive
deficits across various neuropsychological measures and
pronounced affective flattening, resulting in an overall
inferior functional outcome as compared to all other
schizophrenia patients.
Odor naming ability relies on higher cognitive processing
Odor naming but not interpretation was found to depend
on the integrity of higher cognitive processing when
analyzed in all 881 patients. In contrast to Saoud and
coworkers, who investigated only a small number of
individuals [16], we found odor naming, as almost all
neuropsychological tests [26], to correlate with PANSS
negative scores. Due to the low number of odors used
for the naming task in the present work, distributions of
odor naming sum scores were not considered suitable for
the definition of extreme groups. Instead, the definition
was based on interpretation performance. Future studies
will have to aim at doubling the number of odors to be
able to thoroughly explore construct validity of the odor
naming task.
Positive symptoms interfere with odor interpretation
ability
By applying multiple linear regression analyses to inves-
tigate relative association strengths of olfactory target
measures with several symptom domains, odor interpret-
ation, but not naming, was found to be influenced by the
severity of positive symptoms. In fact, while the relationship
between basic olfactory processing (e.g. passive odor
identification) and severe negative symptoms is quite well
established [37-41], this is the first study to provide
evidence for psychotic symptoms to interfere with per-
formance in an olfactory function test. This relationship
is supported by imaging studies showing that functional
abnormalities in temporo-limbic regions are related to al-
tered familiarity and hedonicity judgements in schizophrenia
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to the emergence of hallucinations in schizophrenia [43,44].
Based on these findings future studies should address
whether the relationship of odor interpretation and
positive symptom severity is mediated by a dysfunctional
integration of sensory input into cognitive-emotional
processing. The potential for odor interpretation tasks to
indirectly assess the predisposition to develop positive
symptoms should also be further evaluated.
Alertness modulates performance in central olfactory
measures
The large amount of variance shared by odor naming
and interpretation can be partially explained by the
strong association of both olfactory tasks with the level
of alertness. The latter represents the intensity aspect of
attention and comprises both a state of general wakefulness
(intrinsic alertness) and the ability to increase the readiness
to react in response to a cue over a short period of time
(phasic alertness) [45]. Importantly, attention is a require-
ment for assigning the continuous flow of air through the
nose to either respiration or olfactory exploration [46].
Non-attended, the olfactory content of inhalations is
ignored and not processed further. Effects of attentional
modulation on activity in human primary [46] and second-
ary olfactory cortices [47] and amygdala [48] support this
notion. Consequently, the extent to which an individual
attends to a presented odor and is able to maintain the
level of alertness during the completion of a task, likely
influences the amount of resources provided for higher-
order mental operations following the perception of an
olfactory stimulus. Additionally, it is well established that
olfactory (spicy, fruity) and gustatory (salty, sweet) judge-
ments lead to the activation of associated semantic net-
works. This results in a facilitation of olfactory naming – at
least in healthy individuals [25]. However, as the here
applied odor interpretation task was the same for all
odors, differential depth-of-processing effects, potentially
confounding odor naming results, can be excluded.
Odor interpretation is associated with discrete
neuropsychological functions
Comparisons of low and high odor interpretation per-
formers (HIP / LIP) with regard to single neuropsycho-
logical measures revealed largest group differences for
reasoning abilities. Processing speed and working memory
also differed significantly dependent on odor interpretation
performance whereas executive functioning (set shifting),
verbal memory and divided attention did not. Together,
these findings should stimulate further research into
primary cognitive functions involved in the odor inter-
pretation task.
Of note is the fact that premorbid intelligence, age-
at-prodrome and age-of-onset of schizophrenia showedat least a strong tendency of a difference between LIP
and HIP, indicating a potentially more pronounced
neurodevelopmental aspect of the disease in LIP. This
difference alone, however, is unlikely to explain the marked
contrast in psychopathology and cognition between ex-
treme groups since post hoc linear regression models
remained significant upon inclusion of neurodevelopmental
variables as covariates (data not shown).
Conclusions
Although further work is needed to improve psychometric
properties of the measures by e.g. increasing the number
of applied odors, we deliver first evidence for both
tasks to accentuate slightly dissimilar aspects of higher
brain functioning. Future studies are needed to delineate
whether prevailing impairment in either odor naming
or interpretation indicates a preferential lack of integrity
in either sensory-cognitive or sensory-emotional brain
networks. If developed into psychometrically sound
tests, odor naming and interpretation tasks could assist the
delineation of biologically defined disease subphenotypes,
characterized by preponderance of either cognitive decline/
negative symptoms, or of pronounced positive symptoms.
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